These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22791274)

  • 21. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
    Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
    Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
    Subissi A; Monti D; Togni G; Mailland F
    Drugs; 2010 Nov; 70(16):2133-52. PubMed ID: 20964457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
    Barrett YC; Wang J; Song Y; Pursley J; Wastall P; Wright R; Lacreta F; Frost C
    Thromb Haemost; 2012 May; 107(5):916-24. PubMed ID: 22398784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon.
    Visser LE; Penning-van Beest FJ; Wilson JH; Vulto AG; Kasbergen AA; De Smet PA; Hofman A; Stricker BH
    Br J Clin Pharmacol; 2004 Apr; 57(4):522-4. PubMed ID: 15025752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
    Bohn M; Kraemer KT
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Interaction between Acenocoumarol and Linezolid.
    Ghosh K; Ghosh K
    J Assoc Physicians India; 2017 Sep; 65(9):107. PubMed ID: 29313591
    [No Abstract]   [Full Text] [Related]  

  • 27. Possible interaction between topical terbinafine and acenocoumarol.
    Morales-Molina JA; Arrebola MA; Robles PA; Mangana JC
    Ann Pharmacother; 2009 Nov; 43(11):1911-2. PubMed ID: 19843835
    [No Abstract]   [Full Text] [Related]  

  • 28. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
    Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
    Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests].
    Nagler M; Wuillemin W
    Ther Umsch; 2012 Nov; 69(11):650-6. PubMed ID: 23117668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin.
    Ceschin-Roques CG; Hänel H; Pruja-Bougaret SM; Luc J; Vandermander J; Michel G
    Skin Pharmacol; 1991; 4(2):89-94. PubMed ID: 1831626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ciclopirox delivery into the human nail plate.
    Hui X; Wester RC; Barbadillo S; Lee C; Patel B; Wortzmman M; Gans EH; Maibach HI
    J Pharm Sci; 2004 Oct; 93(10):2545-8. PubMed ID: 15349963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation.
    Vlachos K; Efremidis M; Bazoukis G; Letsas KP; Saplaouras A; Georgopoulos S; Karamichalakis N; Rokiza A; Sakellaropoulou A; Kolokathis AM; Efremidis T; Asvestas D; Sideris A
    Clin Cardiol; 2017 Oct; 40(10):847-852. PubMed ID: 28561951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.
    Carcas AJ; Borobia AM; Velasco M; Abad-Santos F; Díaz MQ; Fernández-Capitán C; Ruiz-Giménez N; Madridano O; Sillero PL;
    Trials; 2012 Dec; 13():239. PubMed ID: 23237631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The management of coumarin-induced over-anticoagulation Annotation.
    Makris M; Watson HG
    Br J Haematol; 2001 Aug; 114(2):271-80. PubMed ID: 11529844
    [No Abstract]   [Full Text] [Related]  

  • 35. Which oral anticoagulant for atrial fibrillation.
    Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.
    Penning-van Beest FJ; van Meegen E; Rosendaal FR; Stricker BH
    Clin Pharmacol Ther; 2001 Jun; 69(6):451-7. PubMed ID: 11406743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory tests and the new oral anticoagulants.
    Tripodi A
    Thromb Res; 2012 Oct; 130 Suppl 1():S95-7. PubMed ID: 23026677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemoptysis Associated With Therapeutic Doses of Acenocoumarol.
    Cerezo Lajas A; Rodríguez Guzmán MDC; de Miguel Díez J
    Arch Bronconeumol (Engl Ed); 2019 Jun; 55(6):341-342. PubMed ID: 30528810
    [No Abstract]   [Full Text] [Related]  

  • 39. Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.
    Robert-Ebadi H; Righini M
    Ther Umsch; 2016; 73(10):618-625. PubMed ID: 28045360
    [No Abstract]   [Full Text] [Related]  

  • 40. Hyperprothrombinemia as a result of a possible warfarin and intravaginal miconazole interaction.
    Thomas JL; Dunn D; Pelletier A; Franks AS
    South Med J; 2010 Oct; 103(10):1063-5. PubMed ID: 20802381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.